Standard Biotools Inc (LAB)

Standard BioTools Inc. is a common stock listed on NASDAQ under the ticker LAB. The company develops, manufactures, and sells instrumentation, consumables, software, and services used by scientists and biomedical researchers to support therapeutic discovery and study biological processes. Its operations are organized into two segments, Proteomics and Genomics. The company’s portfolio includes the SomaScan platform for protein measurement, CyTOF technology for high-parameter analysis using metal-tagged antibodies and mass spectrometry, the Hyperion spatial biology platform for tissue analysis, and the Biomark X9 system for quantitative PCR applications. Standard BioTools markets its research-use products to academic institutions, translational medicine centers, cancer centers, clinical research laboratories, and biopharmaceutical, biotechnology, and plant and animal research companies across the Americas, Europe, the Middle East, Africa, and Asia Pacific. Founded in 1999 and headquartered in South San Francisco, California, the company was formerly known as Fluidigm Corporation and adopted its current name in April 2022.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.